JP2013523190A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523190A5 JP2013523190A5 JP2013505183A JP2013505183A JP2013523190A5 JP 2013523190 A5 JP2013523190 A5 JP 2013523190A5 JP 2013505183 A JP2013505183 A JP 2013505183A JP 2013505183 A JP2013505183 A JP 2013505183A JP 2013523190 A5 JP2013523190 A5 JP 2013523190A5
- Authority
- JP
- Japan
- Prior art keywords
- toxin
- antibody
- antigen
- difficile
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 102
- 239000000427 antigen Substances 0.000 claims 83
- 102000036639 antigens Human genes 0.000 claims 82
- 108091007433 antigens Proteins 0.000 claims 82
- 241000193163 Clostridioides difficile Species 0.000 claims 76
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 76
- 101710182532 Toxin a Proteins 0.000 claims 76
- 101710182223 Toxin B Proteins 0.000 claims 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 229920001184 polypeptide Polymers 0.000 claims 39
- 102000004196 processed proteins & peptides Human genes 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 230000003472 neutralizing effect Effects 0.000 claims 21
- 210000004408 hybridoma Anatomy 0.000 claims 16
- 230000002401 inhibitory effect Effects 0.000 claims 14
- 239000003053 toxin Substances 0.000 claims 14
- 231100000765 toxin Toxicity 0.000 claims 14
- 108700012359 toxins Proteins 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 230000001988 toxicity Effects 0.000 claims 11
- 231100000419 toxicity Toxicity 0.000 claims 11
- 230000001717 pathogenic effect Effects 0.000 claims 9
- 102000005962 receptors Human genes 0.000 claims 8
- 108020003175 receptors Proteins 0.000 claims 8
- 108091008324 binding proteins Proteins 0.000 claims 7
- 102000023732 binding proteins Human genes 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 7
- 230000010534 mechanism of action Effects 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 5
- 230000001147 anti-toxic effect Effects 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 4
- 102000004190 Enzymes Human genes 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 230000002860 competitive effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000003053 immunization Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 241001112695 Clostridiales Species 0.000 claims 3
- 230000000903 blocking effect Effects 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims 2
- 206010012735 Diarrhoea Diseases 0.000 claims 2
- 102000000340 Glucosyltransferases Human genes 0.000 claims 2
- 108010055629 Glucosyltransferases Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- KGZHFKDNSAEOJX-WIFQYKSHSA-N Ramoplanin Chemical compound C([C@H]1C(=O)N[C@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C)C(=O)N[C@H](C(=O)O[C@@H]([C@@H](C(N[C@@H](C(=O)N[C@H](CCCN)C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)[C@H](C)O)C=1C=CC(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O)=CC=1)=O)NC(=O)[C@H](CC(N)=O)NC(=O)\C=C/C=C/CC(C)C)C(N)=O)C=1C=C(Cl)C(O)=CC=1)C=1C=CC(O)=CC=1)[C@@H](C)O)C=1C=CC(O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=1)C1=CC=CC=C1 KGZHFKDNSAEOJX-WIFQYKSHSA-N 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 claims 2
- 239000003899 bactericide agent Substances 0.000 claims 2
- 239000000022 bacteriostatic agent Substances 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 230000007246 mechanism Effects 0.000 claims 2
- 229960000282 metronidazole Drugs 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- 229960002480 nitazoxanide Drugs 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 230000002797 proteolythic effect Effects 0.000 claims 2
- 229950003551 ramoplanin Drugs 0.000 claims 2
- 108010076689 ramoplanin Proteins 0.000 claims 2
- 229960003040 rifaximin Drugs 0.000 claims 2
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 229960003165 vancomycin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 1
- 108010076667 Caspases Proteins 0.000 claims 1
- 102100029727 Enteropeptidase Human genes 0.000 claims 1
- 108010013369 Enteropeptidase Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000007541 cellular toxicity Effects 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- -1 fidaxomycin Chemical compound 0.000 claims 1
- 230000008348 humoral response Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003405 preventing effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000006337 proteolytic cleavage Effects 0.000 claims 1
- 230000001603 reducing effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 101150089436 tcdB gene Proteins 0.000 claims 1
- 230000005945 translocation Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32450310P | 2010-04-15 | 2010-04-15 | |
| US61/324,503 | 2010-04-15 | ||
| US38166910P | 2010-09-10 | 2010-09-10 | |
| US61/381,669 | 2010-09-10 | ||
| PCT/US2011/032713 WO2011130650A2 (en) | 2010-04-15 | 2011-04-15 | Antibodies for the treatment of clostridium difficile-associated infection and disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016131227A Division JP6159854B2 (ja) | 2010-04-15 | 2016-07-01 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523190A JP2013523190A (ja) | 2013-06-17 |
| JP2013523190A5 true JP2013523190A5 (enExample) | 2014-05-29 |
| JP5965389B2 JP5965389B2 (ja) | 2016-08-03 |
Family
ID=44799348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013505183A Active JP5965389B2 (ja) | 2010-04-15 | 2011-04-15 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
| JP2016131227A Active JP6159854B2 (ja) | 2010-04-15 | 2016-07-01 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016131227A Active JP6159854B2 (ja) | 2010-04-15 | 2016-07-01 | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8986697B2 (enExample) |
| EP (1) | EP2558493B1 (enExample) |
| JP (2) | JP5965389B2 (enExample) |
| KR (1) | KR101820987B1 (enExample) |
| CN (1) | CN102947334B (enExample) |
| AU (1) | AU2011239470B2 (enExample) |
| BR (1) | BR112012026021B1 (enExample) |
| CA (1) | CA2795953C (enExample) |
| ES (1) | ES2757675T3 (enExample) |
| MX (1) | MX339253B (enExample) |
| WO (1) | WO2011130650A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5965389B2 (ja) | 2010-04-15 | 2016-08-03 | プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
| EP3167899B1 (en) | 2010-09-03 | 2021-03-24 | Valneva Austria GmbH | Isolated polypeptide of the toxin a and toxin b proteins of c.difficile and uses thereof |
| CA2845884A1 (en) | 2011-08-22 | 2013-02-28 | Cangene Corporation | Clostridium difficile antibodies |
| WO2013038156A1 (en) * | 2011-09-16 | 2013-03-21 | Ucb Pharma S.A. | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| SG11201402375VA (en) * | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| CN102590515B (zh) * | 2012-01-13 | 2014-07-30 | 张春华 | 艰难梭菌外毒素a检测试剂盒及组成该试剂盒的单克隆抗体 |
| AU2013212264B2 (en) * | 2012-01-23 | 2017-05-18 | Santalis Pharmaceuticals Inc. | Sandalwood oil and its uses related to clostridium infections |
| RU2628305C2 (ru) | 2012-03-02 | 2017-08-15 | Регенерон Фармасьютиказ, Инк. | Человеческие антитела к токсинам clostridium difficile |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| EP2921502A4 (en) | 2012-10-19 | 2016-09-28 | Evec Inc | AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY |
| JP2016501877A (ja) * | 2012-11-28 | 2016-01-21 | シーエヌジェー ホールディングス，インコーポレイテッド | クロストリジウム・ディフィシルに対する抗体 |
| CN107880126B (zh) | 2012-12-21 | 2021-03-30 | 西雅图基因公司 | 抗ntb-a抗体及相关组合物和方法 |
| EP4079760A3 (en) | 2013-03-15 | 2023-01-25 | Sanofi Pasteur Inc. | Antibodies against clostridium difficile toxins and methods of using the same |
| CN105555309A (zh) * | 2013-04-19 | 2016-05-04 | 英穆伦有限公司 | 治疗和/或预防艰难梭菌相关疾病的方法和组合物 |
| CA2910200A1 (en) | 2013-04-22 | 2014-10-30 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| EP2957570B1 (en) | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyclonal antibodies against clostridium difficile and uses thereof |
| WO2016156474A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a |
| WO2016156475A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b |
| JP2018517670A (ja) * | 2015-04-15 | 2018-07-05 | メディミューン，エルエルシー | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）感染および関連疾患の治療方法 |
| GB201509326D0 (en) * | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| EP3344276B1 (en) | 2015-09-03 | 2020-04-22 | The Board of Regents of the University of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
| SG11201808246SA (en) * | 2016-03-24 | 2018-10-30 | Paratek Pharm Innc | Methods for treating and preventing c. difficile infection |
| US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189964A2 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018148537A1 (en) * | 2017-02-10 | 2018-08-16 | Stc. Unm | Recombinant expression systems and products |
| JP7339262B2 (ja) * | 2018-01-12 | 2023-09-05 | アムジェン インコーポレイテッド | Ｐａｃ１抗体及びその使用 |
| GB201807367D0 (en) * | 2018-05-04 | 2018-06-20 | Univ Newcastle | Biomarker |
| RU2694549C1 (ru) * | 2018-08-16 | 2019-07-16 | Федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр здоровья детей" Министерства здравоохранения Российской Федерации (ФГАУ "НМИЦ здоровья детей" Минздрава России) | Способ ведения детей с болезнью Гиршпрунга в периоперационном периоде |
| WO2021219786A1 (en) * | 2020-04-30 | 2021-11-04 | Gottfried Himmler | Anti-toxin secretory iga2 preparation |
| CN111499738B (zh) * | 2020-06-03 | 2022-04-05 | 郑州师范学院 | 一种抗艰难梭菌肠毒素a的抗体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5292668A (en) | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| US4879218A (en) * | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US6071517A (en) | 1986-07-07 | 2000-06-06 | Medarex, Inc. | Bispecific heteroantibodies with dual effector functions |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| DK1766093T3 (da) * | 2004-02-06 | 2011-10-03 | Univ Massachusetts | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| EP1833510A4 (en) * | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
| US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| EP2033657A1 (de) | 2007-09-04 | 2009-03-11 | Trion Pharma Gmbh | Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination |
| JP5965389B2 (ja) | 2010-04-15 | 2016-08-03 | プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
-
2011
- 2011-04-15 JP JP2013505183A patent/JP5965389B2/ja active Active
- 2011-04-15 US US13/641,315 patent/US8986697B2/en active Active
- 2011-04-15 EP EP11769680.7A patent/EP2558493B1/en active Active
- 2011-04-15 KR KR1020127029208A patent/KR101820987B1/ko active Active
- 2011-04-15 AU AU2011239470A patent/AU2011239470B2/en active Active
- 2011-04-15 BR BR112012026021-9A patent/BR112012026021B1/pt active IP Right Grant
- 2011-04-15 CN CN201180024312.0A patent/CN102947334B/zh active Active
- 2011-04-15 WO PCT/US2011/032713 patent/WO2011130650A2/en not_active Ceased
- 2011-04-15 MX MX2012011926A patent/MX339253B/es active IP Right Grant
- 2011-04-15 ES ES11769680T patent/ES2757675T3/es active Active
- 2011-04-15 CA CA2795953A patent/CA2795953C/en active Active
-
2015
- 2015-03-09 US US14/642,342 patent/US20150175681A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131227A patent/JP6159854B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523190A5 (enExample) | ||
| CN103732621B (zh) | 抗神经生长因子抗体及其制备和使用方法 | |
| KR101753553B1 (ko) | 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법 | |
| KR101721678B1 (ko) | 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법 | |
| RU2682046C1 (ru) | Il-17a-связывающий агент и способы его применения | |
| KR102166083B1 (ko) | 브라디키닌 b1 수용체 리간드에 대한 항체 | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| CN103764677A (zh) | 抗神经生长因子抗体及其制备和使用方法 | |
| KR20200113228A (ko) | 항-4-1bb 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
| JP2024026170A (ja) | 癌を処置するための組成物及び方法 | |
| US12227583B2 (en) | Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use | |
| TWI685504B (zh) | 抗gitr抗體、其抗原結合片段及其醫藥用途 | |
| JP7014783B2 (ja) | 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用 | |
| RU2012143837A (ru) | АНТИТЕЛА ДЛЯ ЛЕЧЕНИЯ АССОЦИИРОВАННОЙ С Clostridium difficile ИНФЕКЦИИ И ЗАБОЛЕВАНИЯ | |
| WO2019006159A1 (en) | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS | |
| EA047070B1 (ru) | Композиции и способы лечения рака | |
| HK40036534A (en) | Heavy chain antibodies binding to cd22 | |
| HK40015379A (en) | Therapeutic anti-cd40 ligand antibodies | |
| HK1229710A1 (en) | Compositions and methods for treating and preventing staphylococcus aureus infections | |
| HK1236389B (en) | Compositions and methods for treating and preventing staphylococcus aureus infections |